
-
US and China prepare for trade talks as Trump floats tariff cut
-
US projected to hit debt limit in August: Treasury chief
-
'You're gonna be the Pope,' Leo XIV's brother recalls telling him
-
Guardiola says Man City season has been toughest in management
-
'It's terrific': Chicago hails hometown hero Pope Leo XIV
-
Europe leaders head to Kyiv on unprecedented visit
-
Pakistan warns won't de-escalate as conflict with India spirals
-
Stocks mixed as global markets eye US-China tariff talks
-
Serbia's Vucic seeks low-price gas in Putin meeting
-
German Holocaust survivor and witness-bearer Margot Friedlaender dies at 103
-
Timberwolves launch probe after fan's 'racially charged' abuse
-
Giro over for Landa after high-speed opening stage crash
-
US approves first at-home cervical cancer screening device
-
FIFA Women's World Cup expanded to 48 teams from 2031
-
Mitchell leads, Lowry charges and Rory five back at rainy Truist
-
Gauff holds nerve to join Sabalenka in Italian Open third round
-
Israel not involved in Gaza food distribution under US aid plan: envoy
-
Margot Friedlaender, Germany's voice of Holocaust remembrance
-
Fallen giant Hamburg close in on top-flight redemption
-
Dozens of minors killed in Mexico cartel infighting
-
Trump fires librarian of US Congress
-
Spurs will show no fear against Man Utd in Europa League final: Van de Ven
-
Renowned Holocaust survivor Margot Friedlaender dies at 103
-
Woods, 16-year-old Charlie, misses out in US Open qualifier
-
Pakistan says India has put neighbours 'closer to major conflict'
-
On patrol for jihadists with Mauritania's camel cavalry
-
France, Poland sign treaty with mutual defence pledge
-
NATO chief seeks defence spending at 5% of GDP by 2032: Dutch PM
-
La Rochelle head coach O'Gara suspended for five weeks
-
Measles roars back in the US, topping 1,000 cases
-
Fulham boss Silva refuses to rule out Saudi switch
-
From Chicago to Chiclayo: Peruvian town hails adoptive son and pope
-
Ivorian women fight FGM with reconstructive surgery
-
Pedersen wins opening stage of Giro d'Italia in Albania
-
Stocks mixed despite hopes for US-China tariff talks
-
US, Swiss agree to speed up tariff talks
-
Trump floats cutting China tariffs to 80% ahead of trade talks
-
Pedersen wins opening stage of Giro d'Italia
-
Marc Marquez sets Le Mans lap record in French MotoGP practice
-
Jungle music: Chimp drumming reveals building blocks of human rhythm
-
Guardiola tells Man City stars to question their hunger after troubled season
-
Putin, Xi, Steven Seagal and missiles: Russia's Red Square parade
-
Trump suggests lower 80% China tariff ahead of Geneva trade talks
-
Arteta wants Arsenal to use Liverpool guard of honour as title fuel
-
Stocks lifted by hopes for US-China talks
-
Putin hails troops in Ukraine as allies attend WWII parade
-
UK, northern European nations support Ukraine 30-day ceasefire: Norway PM
-
Activists hold 'die-in' protest at Soviet monument in Warsaw
-
Trump suggests lower China tariff, says 80% 'seems right!'
-
Alonso confirms exit from Leverkusen at end of season

CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis
CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative therapies for high incidence immuno-dermatological disorders, today announced the initiation of a Phase 2b dose-ranging trial for its CGB-500 product. This topical JAK inhibitor ointment, developed using CAGE Bio's proprietary ionic liquid technology, represents a potential breakthrough for low body surface area (BSA), moderate to severe atopic dermatitis (AD) condition.
CGB-500 delivers medicine directly through the skin, combining high efficacy with minimal systemic exposure. Results from the 2024 Phase 2a trial showed efficacy comparable to biologics, outperforming current best-in-class topical treatments while maintaining a significantly lower side-effect profile. Specifically, CGB-500 had an 8-week treatment success of 95% (IGA score of "0" or "1" and > 2 grade improvement ).
This larger Phase 2b trial (n=180) will focus on optimizing dosing regimens and further assessing the safety and efficacy of CGB-500. This pivotal step underscores CAGE Bio's commitment to addressing the unmet needs of patients with moderate to severe AD and low body surface area (BSA) involvement, where treatment speed and efficacy must be balanced with the cost of systemic exposure and side effects.
"CGB-500 offers a promising solution for patients seeking rapid and effective localized relief potentially avoiding systemic therapies and their associated side-effects" said Dr. Justin Ko MD, a board-certified dermatologist in San Francisco Bay Area.
"Our ionic liquid platform continues to demonstrate its potential in enabling highly effective and targeted topical therapies. With the Phase 2b trial now underway, we are one step closer to transforming how atopic dermatitis is treated," said Nitin Joshi, Ph.D., CEO of CAGE Bio.
Atopic dermatitis is a chronic inflammatory skin condition affecting millions globally. Patients with highly localized, moderate to severe symptoms face limited treatment options. CGB-500 seeks to fill this gap, offering a high efficacy alternative with dramatically lower systemic exposure.
CAGE Bio remains committed to advancing clinical programs that deliver transformative therapies (efficacy of a biologic with safety of a topical ) for immuno-dermatological disorders.
About CAGE Bio
CAGE Bio is a clinical-stage biotechnology company developing innovative localized therapies for immune-mediated dermatological conditions. Its proprietary ionic liquid technology ensures effective drug delivery to target areas with minimal systemic exposure, improving patient outcomes.
Phone: +1 (650) 996-1845
email. [email protected]
SOURCE: CAGE Bio Inc.
O.Norris--AMWN